Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV

Inclusion Criteria: * Patient age \< 22 years. * Both genders and all races are eligible. * The patient population chosen for the T-cell depleted allogeneic HPCT from a related or unrelated allogeneic donor must meet eligibility based on institutional SOPs and/or the IRB approved T cell depleted allogeneic HPCT protocol which they are enrolled. * Must be willing to sign a written informed consent. * Patient Organ Status at the time of enrollment (pre-transplant) * Lansky or Karnofsky score \> 50 * Echocardiogram shortening fraction \> 27% * Renal function: serum creatinine \< 2 x normal for age * DLCO \> 50% predicted in patients old enough to comply with PFTs or no baseline oxygen requirement for younger patients. * Hepatic: AST, ALT \< 5x upper limit of normal; bilirubin \< 2.0 mg/dl * Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months following CTL infusion. The male partner should use a condom. * Patients must be between 28 and 100 days post T-cell depleted allogeneic HPCT * Patients must meet the following criteria (within 72 hours of CTL infusion): * Achieved primary engraftment with an ANC of at least 1000 per μl for 3 consecutive days. * No oxygen requirement with oxygen saturations \> 90%. * AST, ALT \< 5x upper limit of normal for age; bilirubin \< 2 mg/dl. * Hemoglobin \> 8 gm/dl prior to infusion. (May be transfusion dependent). * Renal function: serum creatinine \< 2 x normal for age. * The Patient must not have the following conditions on the day of CTL infusion: * Exhibit overt hematologic manifestations of relapse or persistent disease. * Evidence of recurrent/persistent disease based primarily on flow cytometry, cytogenetics, chimerism analysis, or other molecular studies does not by itself represent grounds for exclusion. Exclusion Criteria: * Currently enrolled on another Phase I clinical trial. * Pregnant or nursing * Overt hematologic manifestations of relapse or persistent disease * Having \> grade 1 graft-versus-host disease.